Wall Street analyst estimates for Bolt Biotherapeutics, Inc. (BOLT): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2).
Analyst Consensus
| Strong Buy | 0 |
| Buy | 3 |
| Hold | 5 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 8 |
| Avg rating (1-5) | 0.38 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-11 | $-3.89 | ||
| 2026-08-11 | $-4.57 | $-3.39 | -34.8% |
| 2026-05-12 | $-4.31 | $-2.85 | -51.2% |
| 2026-03-12 | $-3.84 | $-4.30 | +10.7% |
| 2025-11-12 | $-3.72 | $-5.07 | +26.6% |
| 2025-08-14 | $-4.46 | $-6.40 | +30.3% |
| 2025-05-12 | $-5.80 | $-6.80 | +14.7% |
| 2025-03-24 | $-7.60 | $-7.60 | +0.0% |
Valuation Ratios
| Price / Book | 0.49 |
| EV / EBITDA | -0.67 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | $215000 | $231000 | $1.3M | $5.7M | $7.9M | $7.7M | $7.7M |
| Cost of Revenue | $302000 | 0 | $40.4M | $75.7M | $73.1M | $61.5M | 0 | $1.5M |
| Gross Profit | -$302000 | $215000 | -$40.1M | -$74.4M | -$67.4M | -$53.7M | $7.7M | $6.2M |
| Research & Development | $9.4M | $26.0M | $40.4M | $75.7M | $73.1M | $61.5M | $57.5M | $28.5M |
| Selling, General & Admin | $2.2M | $5.2M | $9.1M | $18.4M | $22.9M | $22.5M | $18.5M | $13.8M |
| Operating Expenses | $11.6M | $31.2M | $9.1M | $18.4M | $22.9M | $22.5M | $80.7M | $40.8M |
| Operating Income | -$11.6M | -$31.0M | -$49.2M | -$92.8M | -$90.3M | -$76.2M | -$73.0M | -$34.6M |
| EBITDA | -$11.3M | -$30.6M | -$48.6M | -$97.4M | -$86.4M | -$67.3M | -$66.5M | -$31.9M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$11.6M | -$30.5M | -$60.7M | -$98.6M | -$88.1M | -$69.2M | -$63.1M | -$33.4M |
| Income Tax | $40000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$11.6M | -$30.5M | -$60.7M | -$98.6M | -$88.1M | -$69.2M | -$63.1M | -$33.4M |
| EPS | $-5.96 | $-3.75 | $-1.99 | $-2.79 | $-2.30 | $-1.83 | $-1.65 | $-17.85 |
| EPS (Diluted) | $-5.96 | $-3.75 | $-1.99 | $-2.79 | $-2.30 | $-1.83 | $-1.65 | $-17.85 |
| Shares Outstanding (Diluted) | $97186 | $400497 | $1.8M | $1.9M | $1.9M | $1.9M | $1.9M | $1.9M |
Price
| Price | $3.63 |
| Market Cap | $7M |
| Exchange | NASDAQ |
| Country | US |
Related companies: AEON · CING · CLRB · EVGN · IMNN · INAB · LYRA
Explore sector: Healthcare · Biotechnology
More sections of BOLT: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks